Iteos Therapeutics Inc
iTeos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of T-cell immunoreceptor with Ig and ITIM domains (TIGIT), as well as engages the Fc gamma receptor to activate dendritic cells, natural killer cells, T lym… Read more
Iteos Therapeutics Inc (ITOS) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: -0.086x
Based on the latest financial reports, Iteos Therapeutics Inc (ITOS) has a cash flow conversion efficiency ratio of -0.086x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-42.45 Million) by net assets ($493.80 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Iteos Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Iteos Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Iteos Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Iteos Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Zhejiang Kan Specialities Material Co Ltd
SHE:002012
|
-0.005x |
|
Arafura Resources Limited
DU:REB
|
-0.131x |
|
Akebia Ther
NASDAQ:AKBA
|
0.955x |
|
Sella Capital Real Estate Ltd
PINK:STCPF
|
0.021x |
|
Hynar Water Group Co. Ltd.
SHE:300961
|
N/A |
|
SHIZUOKA GAS CO. LTD.
F:1KS
|
N/A |
|
Sichuan Zhongguang Lightning Protection Technologies Co Ltd
SHE:300414
|
0.005x |
|
Henan Huaying Agricultural Development Co Ltd
SHE:002321
|
0.036x |
Annual Cash Flow Conversion Efficiency for Iteos Therapeutics Inc (2018–2024)
The table below shows the annual cash flow conversion efficiency of Iteos Therapeutics Inc from 2018 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $590.29 Million | $-98.18 Million | -0.166x | +7.79% |
| 2023-12-31 | $575.23 Million | $-103.76 Million | -0.180x | -7.60% |
| 2022-12-31 | $663.33 Million | $-111.19 Million | -0.168x | -118.06% |
| 2021-12-31 | $552.82 Million | $513.14 Million | 0.928x | +1291.61% |
| 2020-12-31 | $323.20 Million | $-25.18 Million | -0.078x | +94.73% |
| 2019-12-31 | $15.67 Million | $-23.14 Million | -1.477x | -16.43% |
| 2018-12-31 | $15.05 Million | $-19.10 Million | -1.269x | -- |